Browse

Assessments

1,354 results

IDDrugIndicationAreaTypeBenefit ratingPublished
A26-51NipocalimabHead and nervesAddendum
Not proven
2026-06-18
A25-160NipocalimabHead and nervesInitial
Not proven
2026-06-18
A26-31Niraparib/abiraterone acetateCancerInitial
Not proven
2026-06-15
A26-30imlunestrantER-positive, HER2-negative, locally advanced or metastatic breast cancer with activating ESR1 mutation, after prior endocrine therapyOncologyInitial
Not provenMinor
2026-06-15
A26-27InebilizumabHead and nervesInitial
Not proven
2026-06-15
A26-26InebilizumabImmune system and infectionsInitial
Not proven
2026-06-15
A26-25MepolizumabAirways and respiratory systemInitial
Not proven
2026-06-15
A26-45nivolumaburothelial carcinoma, adjuvant treatmentCancerAddendum
MinorNot proven
2026-06-05
A26-44cemiplimabcutaneous squamous cell carcinoma (adjuvant)CancerAddendum
Not proven
2026-06-05
A26-43iptacopanParoxysmal nocturnal haemoglobinuria (PNH) with haemolytic anaemiaHaematologyAddendum
Not proven
2026-06-05
A25-156IptacopanHaematologyInitial
Not proven
2026-06-05
A25-155CemiplimabCancerInitial
Not proven
2026-06-05
A25-154NivolumabCancerInitial
MinorNot proven
2026-06-05
A25-140pirtobrutinibRelapsed or refractory mantle cell lymphoma in adults previously treated with a Bruton tyrosine kinase (BTK) inhibitorOncology / HaematologyInitial
2026-06-05
A26-18TeprotumumabImmune system and infectionsInitial
Not proven
2026-06-01
A26-17AbemaciclibCancerInitial
Not proven
2026-06-01
A26-16ColchicineHeart and circulationInitial
Non-quantifiable
2026-06-01
A26-15DonidalorsenImmune system and infectionsInitial
Considerable
2026-06-01
A26-14TirzepatideDigestion, metabolism and hormonesInitial
Not proven
2026-06-01
A26-13GadopiclenolDiagnosticsInitial
Not proven
2026-06-01
Page 1 of 68